Table 1.
Baseline characteristics of development and validation cohorts. Values are number (percentage) unless stated otherwise
| Development cohort (n=3622) | External validation cohorts | P value | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| France (n=2649) | Europe and Oceania (n=3327) | North America (n=5891) | |||||||||
| No | Estimate | No | Estimate | No | Estimate | No | Estimate | ||||
| Recipient characteristics | |||||||||||
| Mean (SD) age (years) | 3622 | 51.41 (14.03) | 2649 | 52.55 (13.91) | 3327 | 49.25 (13.38) | 5891 | 52.34 (13.66) | <0.001 | ||
| Male patients | 3622 | 2171 (59.94) | 2649 | 1700 (64.18) | 3327 | 2012 (60.47) | 5891 | 3575 (60.69) | 0.008 | ||
| Mean (SD) BMI | 3622 | 24.76 (4.54) | 2649 | 25.08 (4.49) | 3327 | 25.57 (8.48) | 5793 | 28.42 (6.30) | <0.001 | ||
| Black race | 3622 | 333 (9.19) | 2649 | 150 (5.66) | 3327 | 0.0 (00.00) | 5891 | 448 (7.60) | <0.001 | ||
| Median (IQR) measured GFR (mL/min/1.73m2) | 3622 | 54 (43-66) | 2649 | 49 (36-62) | 3327 | 56 (43-70) | 5891 | 55 (43-68) | <0.001 | ||
| Cause of end stage kidney disease: | |||||||||||
| Glomerulonephritis | 3622 | 903 (24.93) | 1382 | 389 (28.15) | 1079 | 399 (36.98) | 4634 | 1045 (22.55) | <0.001 | ||
| Diabetes | 3622 | 358 (9.88) | 1382 | 138 (9.99) | 1079 | 54 (5.00) | 4634 | 960 (20.72) | |||
| Vascular | 3622 | 319 (8.81) | 1382 | 85 (6.15) | 1079 | 140 (12.97) | 4634 | 424 (9.15) | |||
| Other | 3622 | 2038 (56.27) | 1382 | 770 (55.72) | 1079 | 486 (45.04) | 4634 | 2207 (47.63) | |||
| Donor characteristics | |||||||||||
| Mean (SD) age (years) | 3622 | 51.01 (16.04) | 711 | 51.71 (15.72) | 2894 | 50.77 (14.08) | 5748 | 43.36 (14.76) | <0.001 | ||
| Male patient | 3087 | 1640 (53.13) | 1843 | 1027 (55.75) | 1155 | 639 (55.32) | 5749 | 2721 (47.33) | <0.001 | ||
| Hypertension | 2708 | 461 (17.02) | 929 | 155 (16.68) | 1079 | 424 (39.30) | 0 | NA | <0.001 | ||
| Diabetes mellitus | 2969 | 198 (6.67) | 783 | 40 (5.11) | 1079 | 66 (6.12) | 0 | NA | <0.001 | ||
| Creatinine >1.5 mg/dL | 3556 | 365 (10.26) | 1184 | 167 (14.10) | 862 | 126 (14.62) | 0 | NA | <0.001 | ||
| Deceased donor | 3610 | 2890 (80.06) | 1574 | 1402 (89.07) | 1079 | 1059 (98.15) | 5891 | 2349 (39.87) | <0.001 | ||
| Transplant baseline characteristics | |||||||||||
| Previous kidney transplant | 3106 | 551 (17.74) | 688 | 34 (4.94) | 1079 | 80 (7.41) | 4910 | 698 (14.22) | <0.001 | ||
| Delayed graft function | 3564 | 881 (24.72) | 1101 | 154 (13.99) | 963 | 223 (23.16) | 5649 | 689 (12.20) | <0.001 | ||
| Mean (SD) cold ischaemia time in deceased donors (hours) | 3111 | 16.13 (10.20) | 1765 | 15.85 (7.15) | 749 | 19.8 (13.40) | 4279 | 7.62 (10.39) | <0.001 | ||
| Mean (SD) No of HLA-A, B, or DR mismatches | 3111 | 4.30 (1.39) | 2168 | 3.54 (1.31) | 1065 | 3.05 (1.12) | 5624 | 3.41 (1.71) | <0.001 | ||
BMI=body mass index; GFR=glomerular filtration rate; HLA=human leucocyte antigen; IQR=interquartile range; NA=not available; SD=standard deviation.
1 mg/dL creatinine=88.4 μmol/L.